The objective of this study is to determine the effects of adjunct exercise in treatment resistant depression. The central hypothesis for the research is that adjunct exercise with usual care in Treatment Resistant Depression (TRD) will have significant effects in improving the psychiatric symptoms in comparison to usual care alone.
Participants with treatment resistant depression will be recruited to participate in a 12-week clinical trial on the effects of adjunct moderate-intensity exercise versus usual care. Primary outcome measure will be reduction in baseline scores on Hamilton Depression Rating Scale (17 item). Secondary outcome measure will include reduction in baseline scores of clinical global impression severity, pittsburgh sleep quality index global score, scores on beck depression inventory, and improvement in actigraphic sleep.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Change from baseline on Hamilton Rating Scale for Depression-17 item (HRSD17)score
Hamilton Rating Scale for Depression-17 item (HRSD17, a well standardized measure of depression will be the primary measures of efficacy.
Time frame: Baseline, 6 weeks, and 12 weeks
Reduction in baseline scores of clinical global impression severity
Time frame: Baseline, 6 weeks, and 12 weeks
Change from baseline on Beck Depression Inventory-II score
This is a widely used reliable and standardized measure of depression.
Time frame: Baseline, 6 weeks, 12 weeks
Change from baseline on Pittsburgh Sleep Quality Index (PSQI) global sleep quality score
PSQI is a widely used, reliable and standardized measure of subjecitve sleep
Time frame: baseline, 6 weeks, 12 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.